MS
BBIO icon

Maven Securities’s BridgeBio Pharma BBIO Stock Holding History

Maven Securities’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-39,850
Closed -$1.02M – 206
2019
Q2 		$1.02M Buy
+39,850
New +$1.09M 0.68% 38

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maven Securities's BBIO Position: Q3 2019 in Review

Maven Securities sold out of BridgeBio Pharma (BBIO) in Q3 2019, closing a stake of 39,850 shares — an estimated $1.02M sold.

Maven Securities first reported a position in BBIO in Q2 2019 and held it in 1 quarter. The position peaked at $1.02M in Q2 2019. 75 funds tracked by Wall St. Rank hold BBIO as of Q3 2019.

  • Maven Securities reported no remaining BridgeBio Pharma position as of Q3 2019 after selling out during the quarter.
  • Maven Securities sold 39,850 BridgeBio Pharma shares in Q3 2019, an estimated $1.02M.
  • Maven Securities first reported a position in BridgeBio Pharma in Q2 2019 and held it in 1 quarter.
  • Maven Securities's BridgeBio Pharma position peaked at $1.02M in Q2 2019.
  • 75 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2019.

Based on Maven Securities's 13F filing for Q3 2019, filed 14 Nov 2019.